{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059089","form_type":"8-K","ticker":null,"cik":"0001178879","company_name":"AMICUS THERAPEUTICS, INC.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.558921+00:00","generated_at":"2026-06-02T04:57:28.816763+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Amicus Q1 revenue $110.4M (+28% YoY); raises Galafold growth guidance to 13-17%","bullets":["Total revenue $110.4M, up 28% YoY; Galafold net sales $99.4M (+15% YoY).","Pombiliti+Opfolda net sales $11.0M, up 30% from Q4 2023; over 155 patients on/commercial treatment.","GAAP net loss $48.4M ($0.16/sh); non-GAAP net loss $4.6M ($0.02/sh), improved from $16.8M loss in Q1 2023.","Raises full-year Galafold revenue growth guidance to 13-17% (from 11-16%); total revenue growth guided 25-30%.","Cash and securities $239.6M; reiterates full-year non-GAAP profitability projected in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059089","json":"https://secwatch.observer/filing/0001104659-24-059089.json","markdown":"https://secwatch.observer/filing/0001104659-24-059089.md","text":"https://secwatch.observer/filing/0001104659-24-059089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178879/000110465924059089/0001104659-24-059089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178879/000110465924059089/tm2413954d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:57:28.816763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"42d1e332798a2342dd64dd26d975f23ca6335cca","claim":"AMICUS THERAPEUTICS, INC. updated its the first quarter ended March 31, 2024 guidance (raised).","evidence_excerpt":"On May 9, 2024, Amicus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178879/000110465924059089/0001104659-24-059089-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}